



I am pleased to announce the latest step in our journey towards a more sustainable future with the launch of Exelixis' environmental, social and governance (ESG) initiatives – collectively, our ESG values.

At Exelixis, our mission is to help cancer patients recover stronger and live longer. As we strive to extend and improve cancer patients' lives, we also recognize the need to contribute positively to society as a whole. Exelixis expects that our employees will commit to the highest standards of ethical behavior and maintain values and principles that reflect both global awareness and sustainability.

Here on our website, you will find an overview of Exelixis' ESG activities. In this overview, we highlight the Company's sustainable business practices and the progress made in recent years to fulfill our commitment to patients, employees and our community. More specifically, this includes information regarding:

- Our governance and compliance structure
- Our commitment to maximizing innovation and access to our medicines, including our research and development efforts and pricing principles
- Our responsibility to produce safe, high-quality medicines for our patients
- Our efforts to establish and incorporate environmentally sustainable practices into our operations
- Our dedication to hiring and retaining talented employees and creating a safe, productive and supportive company culture

As outlined in [Exelixis' Credo](#), we believe that our dedication to how we work is just as important as the value we bring to those who need our medicines. We truly appreciate the ongoing dialogue with our stakeholders as we have elicited input from numerous groups regarding the ESG issues that are most material and impactful to the Company's current and future activities.

As we close out Exelixis' 25<sup>th</sup> year, our focus remains on continued execution across the organization and doing so with the highest integrity. As we look forward to our future, we will continue integrating ESG considerations directly into our research and development projects, business operations and investment practices as we strive to create sustained value for all our stakeholders by translating science into impact for patients and all those we serve.

I encourage you to read about our ESG activities to see all that has been accomplished so far, as well as our steadfast commitment to contributing to a more sustainable society.

Sincerely,

A handwritten signature in black ink, appearing to read "Michael M. Morrissey". The signature is fluid and cursive, with a large loop at the end.

Michael M. Morrissey, Ph.D.

President and Chief Executive Officer, Exelixis